Condition (MeSH)
Granuloma, Plasma Cell
ClinicalTrials.gov lists 10 trials for Granuloma, Plasma Cell or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with Granuloma, Plasma Cell itself; the rest are tagged with a narrower condition beneath it.
When did Granuloma, Plasma Cell trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 4
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2016 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Granuloma, Plasma Cell trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 2 |
| Phase 2 | 2 |
| Phase 2/3 | 2 |
| Phase 4 | 1 |
| Expanded access | 2 |
How many Granuloma, Plasma Cell trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 3 |
| Terminated | 1 |
| No longer available | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Granuloma, Plasma Cell trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| National Cancer Institute (NCI) | 1 |
| Pfizer | 1 |
| Turning Point Therapeutics, Inc. | 1 |
Which drugs are being tested for Granuloma, Plasma Cell? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Crizotinib | 4 |
| Ceritinib | 3 |
| Repotrectinib | 1 |
| Brigatinib | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ifosfamid | 1 |
| Pazopanib Pill | 1 |
| Doxorubicine | 1 |
| Radiation Therapy | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Granuloma, Plasma Cell trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile neutropenia | 25 | 2 |
| Pyrexia | 20 | 2 |
| Sepsis | 12 | 2 |
| Wound infection | 11 | 2 |
| Abdominal pain | 10 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Granuloma, Plasma Cell? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Immunology of IgG4-related disease. | Clinical and experimental immunology | 2015 | Yes |
| Histological features of pseudotumor-like tissues from metal-on-metal hips. | Clinical orthopaedics and related research | 2010 | Yes |
| Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. | The New England journal of medicine | 2010 | Yes |
| Prospective comparative study of the EUS guided 25-gauge FNA needle with the 19-gauge Trucut needle and 22-gauge FNA needle in patients with solid pancreatic masses. | Journal of gastroenterology and hepatology | 2009 | Yes |
| Endoscopic ultrasound-guided fine needle aspiration biopsy for splenic tumor: a case series. | Endoscopy | 2009 | Yes |
Showing 5 of 7 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.